Thousands of patients suffering from HAE will have access to medicines for the first time, with the launch of the HAEi Global Access Program, a landmark medication access program.
HAEi is proud to announce the HAEi Global Access Program (HAEi GAP).
It is the first time that a patient group has initiated this type of medication distribution program.
The HAEi GAP model initially includes a ‘Named Patient Program’ where governments/hospitals order the medicine and provide reimbursement. Later it is also planned to include a ‘Compassionate Use Program’ that offers donated medication to patients in parts of the world where this type of program is allowed, and an ‘Early Access Program’ where access to medication will be given in conjunction with a phase III clinical trial.
The first pharmaceutical company in HAEi GAP is Pharming Group.
HAEi GAP enables patients in all countries where Ruconest is not commercially available to gain access to the drug through an ethical and regulatory compliant “Named Patient Program” mechanism.
Simultaneously HAEi is working with other pharmaceutical companies to include other medicines in the program as well.
HAEi GAP is run in partnership with the medicines access company Inceptua.